Unisom is a medication with the active ingredient Diphenhydramine. It is also known by other names like Benadryl and Nytol. Unisom is used to help people fall asleep and to relieve occasional insomnia. It can also be used to treat symptoms of allergies.
Unisom has a price point ranging from £0.53 to £0.74 per pills. Variations in price are linked to the pack’s dimension and the active ingredient dosage (30 or 360 mg).
Unisom contains the active ingredient doxylamine succinate. Doxylamine succinate is an antihistamine that works by blocking certain natural substances (histamine and acetylcholine) that your body makes. It is primarily used for its sedative effects, helping individuals who have difficulty sleeping.
Unisom is available in several pharmaceutical forms, including tablets, capsules, and liquid gels. Each form contains a specific concentration of doxylamine succinate, designed to cater to different patient needs and preferences. Tablets and capsules typically contain 25 mg of the active ingredient, while liquid gels might have slightly varied concentrations.
Unisom is indicated primarily for the short-term treatment of insomnia, particularly when difficulties in falling asleep or maintaining sleep are present. It is also sometimes used in combination with other medications for specific conditions under the direction of a healthcare provider.
The recommended adult dose of Unisom is usually 25 mg, taken 30 minutes before bedtime. However, the dosage may vary based on individual patient needs, underlying health conditions, and response to therapy. For elderly patients, a lower dose may be required due to altered pharmacokinetics and increased sensitivity to the medication.
Doxylamine succinate is a first-generation antihistamine that crosses the blood-brain barrier, leading to its sedative effects. It inhibits the H1 histamine receptors and partially blocks muscarinic receptors, causing drowsiness and facilitating the initiation of sleep.
Following oral administration, doxylamine succinate is well absorbed from the gastrointestinal tract. The onset of action occurs within 30 minutes to an hour. The drug is widely distributed throughout the body and crosses the blood-brain barrier. It is metabolized primarily in the liver and excreted through urine.
Unisom should not be used in individuals who are hypersensitive to doxylamine succinate or any of the medication’s excipients. It is also contraindicated in patients with narrow-angle glaucoma, urinary retention, severe asthma, or chronic obstructive pulmonary disease (COPD) due to the anticholinergic effects.
Concomitant use of Unisom with other central nervous system depressants, such as alcohol, benzodiazepines, or opioids, can potentiate sedative effects. Unisom may also interact with monoamine oxidase inhibitors (MAOIs) and may intensify anticholinergic side effects when used with other anticholinergic agents.
The common side effects of Unisom include dry mouth, drowsiness, dizziness, and headache. Some patients may experience gastrointestinal disturbances such as nausea or constipation. Less commonly, it can cause blurred vision or urinary retention. Long-term use can lead to tolerance and dependence.
For pregnant women, Unisom should be used only if clearly needed and directed by a physician. In breastfeeding mothers, doxylamine succinate passes into breast milk and may cause sedation or other adverse effects in the nursing infant. Pediatric use is not recommended due to the higher risk of adverse reactions.
Store Unisom at room temperature away from light and moisture. Keep it in a secure place out of reach of children and pets. The medication should not be stored in the bathroom, and it is important to keep it in its original packaging to avoid exposure to external elements.
Patients should be instructed to take Unisom exactly as prescribed and not to exceed the recommended dose. They should be made aware of the potential for daytime drowsiness and advised against operating heavy machinery or driving until they know how the medication affects them. It is also important to counsel patients on avoiding alcohol and other sedatives while taking Unisom.
Dosage adjustments may be necessary in patients with hepatic or renal impairment due to the altered metabolism and excretion of the drug. In such cases, a lower starting dose may be appropriate. Regular monitoring by a healthcare provider is advised to ensure safe and effective use of the medication.
The mechanism of action involves the competitive inhibition of peripheral and central H1 receptors, which results in reduced symptoms of allergy and increased propensity for sleep. The drug’s anticholinergic properties contribute to its sedative and hypnotic effects.
Clinical trials and patient reports indicate that Unisom is effective in reducing sleep latency and increasing sleep duration in individuals with transient insomnia. Its efficacy in chronic insomnia is less well established, and long-term usage is generally not recommended due to tolerance and dependency risks.
Unisom should be taken with a full glass of water. Patients are advised to avoid heavy meals close to bedtime, as a full stomach can delay the onset of sleep. Consistent usage at the same time each night can help in establishing a regular sleep routine.
In cases where doxylamine succinate is contraindicated or poorly tolerated, alternative over-the-counter sleep aids containing diphenhydramine or herbal supplements like melatonin may be considered. Consultation with a healthcare provider is recommended for appropriate substitution.
Unisom is intended for short-term use. For long-term management of insomnia, behavioral therapies such as cognitive-behavioral therapy for insomnia (CBT-I) and lifestyle modifications should be considered. These approaches address the underlying causes of insomnia without the risk of medication dependency.
The clinical endpoints for Unisom therapy typically include improved sleep onset latency, increased total sleep time, and improved sleep quality. Subjective measures of patient satisfaction with sleep patterns are also an important endpoint in evaluating treatment efficacy.
Gradual tapering off is usually not necessary given the short-term use, but if dependence is suspected, a gradual reduction in dose may help mitigate withdrawal symptoms. Patients should be monitored for rebound insomnia upon discontinuation.
Doxylamine succinate was introduced as an antihistamine in the mid-20th century. Since then, it has been utilized off-label for its sedative properties. Unisom’s formulation has become a popular over-the-counter remedy for occasional sleeplessness.